Pfizer raises lower end of revenue outlook on Eliquis strength, cuts Covid product forecast

Pfizer has lowered its full‑year revenue forecast for its COVID‑19 products to $4 billion, a reduction from the roughly $5 billion previously projected. The adjustment reflects the company’s assessment of current market conditions and the evolving demand for its COVID‑19 therapeutics and vaccines.

The revised outlook follows a broader industry trend of declining sales as global vaccination rates rise and treatment options diversify. Pfizer’s updated estimate underscores the company’s focus on sustaining profitability while navigating a post‑pandemic market that continues to shift toward other therapeutic areas.

With the new forecast in place, Pfizer will continue to monitor sales performance and adjust its strategy accordingly, aiming to maintain financial stability amid the changing landscape of COVID‑19 product demand.